192 related articles for article (PubMed ID: 10438707)
1. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes.
Falkenburg JH; Wafelman AR; Joosten P; Smit WM; van Bergen CA; Bongaerts R; Lurvink E; van der Hoorn M; Kluck P; Landegent JE; Kluin-Nelemans HC; Fibbe WE; Willemze R
Blood; 1999 Aug; 94(4):1201-8. PubMed ID: 10438707
[TBL] [Abstract][Full Text] [Related]
2. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation.
Smit WM; Rijnbeek M; van Bergen CA; Fibbe WE; Willemze R; Falkenburg JH
Proc Natl Acad Sci U S A; 1998 Aug; 95(17):10152-7. PubMed ID: 9707616
[TBL] [Abstract][Full Text] [Related]
3. Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of alpha-interferon.
Faber LM; van Luxemburg-Heijs SA; Rijnbeek M; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 1996 Feb; 2(1):31-6. PubMed ID: 9078352
[TBL] [Abstract][Full Text] [Related]
4. The progenitor cell inhibition assay to measure the anti-leukemic reactivity of T cell clones against acute and chronic myeloid leukemia.
van der Hoorn MA; van Luxemburg-Heijs SA; van Bergen CA; Bongaerts R; Willemze R; Falkenburg JH
Methods; 2003 Oct; 31(2):113-9. PubMed ID: 12957568
[TBL] [Abstract][Full Text] [Related]
5. Molecular persistence of chronic myeloid leukemia caused by donor T cells specific for lineage-restricted maturation antigens not recognizing immature progenitor-cells.
von dem Borne PA; van Luxemburg-Heijs SA; Heemskerk MH; Jedema I; Mulder A; Willemze R; Falkenburg JH
Leukemia; 2006 Jun; 20(6):1040-6. PubMed ID: 16525495
[TBL] [Abstract][Full Text] [Related]
6. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity.
Faber LM; van Luxemburg-Heijs SA; Veenhof WF; Willemze R; Falkenburg JH
Blood; 1995 Oct; 86(7):2821-8. PubMed ID: 7670118
[TBL] [Abstract][Full Text] [Related]
7. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation.
Marijt E; Wafelman A; van der Hoorn M; van Bergen C; Bongaerts R; van Luxemburg-Heijs S; van den Muijsenberg J; Wolbers JO; van der Werff N; Willemze R; Falkenburg F
Haematologica; 2007 Jan; 92(1):72-80. PubMed ID: 17229638
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia.
Falkenburg JH; Smit WM; Willemze R
Immunol Rev; 1997 Jun; 157():223-30. PubMed ID: 9255633
[TBL] [Abstract][Full Text] [Related]
10. Generation of leukemia-reactive cytotoxic T lymphocytes from HLA-identical donors of patients with chronic myeloid leukemia using modifications of a limiting dilution assay.
Smit WM; Rijnbeek M; van Bergen CA; Willemze R; Falkenburg JH
Bone Marrow Transplant; 1998 Mar; 21(6):553-60. PubMed ID: 9543058
[TBL] [Abstract][Full Text] [Related]
11. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
12. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J
Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403
[TBL] [Abstract][Full Text] [Related]
13. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
[TBL] [Abstract][Full Text] [Related]
14. Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells.
Kloosterboer FM; van Luxemburg-Heijs SA; van Soest RA; Barbui AM; van Egmond HM; Strijbosch MP; Kester MG; Marijt WA; Goulmy E; Willemze R; Falkenburg JH
Leukemia; 2004 Apr; 18(4):798-808. PubMed ID: 14973499
[TBL] [Abstract][Full Text] [Related]
15. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
[TBL] [Abstract][Full Text] [Related]
16. A novel minor histocompatibility antigen recognized by HLA-A31 restricted cytotoxic T lymphocytes generated from HLA-identical bone marrow donor lymphocytes.
Yazaki M; Takahashi T; Andho M; Akatsuka Y; Ito T; Miyake Y; Ito Y; Nakamura S; Wada Y
Bone Marrow Transplant; 1999 Jul; 24(2):129-37. PubMed ID: 10455340
[TBL] [Abstract][Full Text] [Related]
17. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.
de Rijke B; van Horssen-Zoetbrood A; Beekman JM; Otterud B; Maas F; Woestenenk R; Kester M; Leppert M; Schattenberg AV; de Witte T; van de Wiel-van Kemenade E; Dolstra H
J Clin Invest; 2005 Dec; 115(12):3506-16. PubMed ID: 16322791
[TBL] [Abstract][Full Text] [Related]
18. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes.
Falkenburg JH; Goselink HM; van der Harst D; van Luxemburg-Heijs SA; Kooy-Winkelaar YM; Faber LM; de Kroon J; Brand A; Fibbe WE; Willemze R
J Exp Med; 1991 Jul; 174(1):27-33. PubMed ID: 2056279
[TBL] [Abstract][Full Text] [Related]
19. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia.
Choudhury A; Gajewski JL; Liang JC; Popat U; Claxton DF; Kliche KO; Andreeff M; Champlin RE
Blood; 1997 Feb; 89(4):1133-42. PubMed ID: 9028934
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units.
Molldrem JJ; Clave E; Jiang YZ; Mavroudis D; Raptis A; Hensel N; Agarwala V; Barrett AJ
Blood; 1997 Oct; 90(7):2529-34. PubMed ID: 9326217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]